Dissociation of Down syndrome and Alzheimer's disease effects with imaging
Abstract
Down Syndrome (DS) adults experience accumulation of Alzheimer's disease (AD)–like amyloid plaques and tangles and a high incidence of dementia and could provide an enriched population to study AD‐targeted treatments. However, to evaluate effects of therapeutic intervention, it is necessary to dissociate the contributions of DS and AD from overall phenotype. Imaging biomarkers offer the potential to characterize and stratify patients who will worsen clinically but have yielded mixed findings in DS subjects.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 08, 2016
- Source ID
- 10.1016/j.trci.2016.02.004
Entities
People
- Ana S. Lukic
- Boris Marendic
- Dawn C. Matthews
- Down Syndrome Biomarker Initiative And The Alzheimer's Disease Neuroimaging Initiative
- James Brewer
- Lisa Mosconi
- Mark E. Schmidt
- Michael S. Rafii
- Miles N. Wernick
- Randolph D. Andrews
- Robert A. Rissman
- Seth Ness
- Stephen C. Strother
- William C. Mobley
Organizations
- AbbVie
- BioClinica
- Biogen
- Chiron Corporation
- Eli Lilly and Company
- GE HealthCare
- Illinois Institute of Technology
- Janssen Pharmaceutica
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- National Science Foundation
- New York University
- Norman Cousins Center for Psychoneuroimmunology
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of California, San Diego
- University of Toronto